Key Stats for BioNTech Stock
- Price change for BioNTech stock: -18%
- $BNTX Share Price as of Mar. 10: $84
- 52-Week High: $124
- $BNTX Stock Price Target: $136
Now Live: Discover how much upside your favorite stocks could have using TIKR’s new Valuation Model (It’s free)>>>
What Happened?
BioNTech (BNTX) stock fell 18% to its lowest level since August 2024 after the company announced its two co-founders are leaving to start a new venture.
CEO Ugur Sahin and Chief Medical Officer Ozlem Tureci, the married couple who helped create one of the world’s most widely used COVID-19 vaccines, said they are “ready to become pioneers again.”
Both plan to depart by the end of 2026 when their current service agreements end.
The new company will focus on early-stage mRNA research.
BioNTech plans to contribute certain rights and mRNA technologies to the venture in exchange for a minority stake.
Sahin said the budget and headquarters haven’t been decided yet.
The reaction from investors was swift.
One fund manager called it “very bad news” for shareholders, saying BioNTech was losing its “heart and mind.”
On the financial side, BioNTech reported a net loss of EUR 1.14 billion for 2025, wider than the EUR 665 million loss in 2024.
Revenue came in at EUR 2.9 billion.
Despite the losses, the company ended the year with EUR 17.2 billion in cash and securities. That’s a strong cushion.
BioNTech stock still has a lot going for it underneath the headline.
The company has a growing oncology pipeline, a major $11.1 billion partnership with Bristol Myers Squibb, and multiple late-stage clinical readouts expected in 2026.
Management stressed that drug development remains unaffected by the transition.
See analysts’ growth forecasts and price targets for BioNTech stock (It’s free) >>>
What the Market Is Telling Us About BioNTech Stock
The selloff makes sense.
Sahin and Tureci built BioNTech from a startup into a global biotech.
Replacing that kind of leadership is genuinely hard. The market is pricing in real uncertainty.
But BioNTech stock at these levels may be pricing in too much doom. The oncology pipeline is advancing.
The cash position is enormous. And the founders aren’t disappearing overnight.
BioNTech stock is one to watch closely as the company begins its search for new leadership and approaches key data readouts later this year.
Estimate a company’s fair value instantly (Free with TIKR) >>>
How Much Upside Does BioNTech Stock Have From Here?
With TIKR’s new Valuation Model tool, you can estimate a stock’s potential share price in under a minute.
All it takes is three simple inputs:
- Revenue Growth
- Operating Margins
- Exit P/E Multiple
If you’re not sure what to enter, TIKR automatically fills in each input using analysts’ consensus estimates, giving you a quick, reliable starting point.
From there, TIKR calculates the potential share price and total returns under Bull, Base, and Bear scenarios so you can quickly see whether a stock looks undervalued or overvalued.
See a stock’s true value in under 60 seconds (Free with TIKR) >>>
Looking for New Opportunities?
- See what stocks billionaire investors are buying so you can follow the smart money.
- Analyze stocks in as little as 5 minutes with TIKR’s all-in-one, easy-to-use platform.
- The more rocks you overturn… the more opportunities you’ll uncover. Search 100K+ global stocks, global top investor holdings, and more with TIKR.
Disclaimer:
Please note that the articles on TIKR are not intended to serve as investment or financial advice from TIKR or our content team, nor are they recommendations to buy or sell any stocks. We create our content based on TIKR Terminal’s investment data and analysts’ estimates. Our analysis might not include recent company news or important updates. TIKR has no position in any stocks mentioned. Thank you for reading, and happy investing!
